Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2000 Oct 01;1314:756-60. doi: 10.1038/sj.bjp.0703638.
Show Gene links
Show Anatomy links
The antimalarial agent mefloquine inhibits ATP-sensitive K-channels.
Gribble FM
,
Davis TM
,
Higham CE
,
Clark A
,
Ashcroft FM
.
???displayArticle.abstract???
The aim of this study was to determine whether antimalarial agents inhibit ATP-sensitive potassium (K(ATP)) channels and thereby contribute to the observed side-effects of these drugs. Mefloquine (10 - 100 microM), but not artenusate (100 microM), stimulated insulin release from pancreatic islets in vitro. Macroscopic K(ATP) currents were studied in inside-out patches excised from Xenopus oocytes expressing cloned K(ATP) channels. Mefloquine (IC(50) approximately 3 microM), quinine (IC(50) approximately 3 microM), and chloroquine inhibited the pancreatic beta-cell type of K(ATP) channel Kir6.2/SUR1. Artenusate (100 microM) was without effect. Mefloquine and quinine also blocked a truncated form of Kir6.2 (Kir6. 2DeltaC36) when expressed in the absence of SUR1. The extent of block was similar to that observed for Kir6.2/SUR1 currents. Our results suggest that inhibition of the beta-cell K(ATP) channel accounts for the ability of quinoline-based antimalarial drugs to stimulate insulin secretion, and thereby produce hypoglycaemia. The results also indicate that quinoline-based antimalarial agents inhibit K(ATP) channels by interaction with the Kir6.2 subunit. This subunit is common to beta-cell, neuronal, cardiac, skeletal muscle, and some smooth muscle K(ATP) channels suggesting that K(ATP) channel inhibition may contribute to the other side effects of these drugs, which include cardiac conduction abnormalities and neuropsychiatric disturbances.
Aguilar-Bryan,
Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion.
1995, Pubmed
Aguilar-Bryan,
Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion.
1995,
Pubmed
Ashcroft,
Correlating structure and function in ATP-sensitive K+ channels.
1998,
Pubmed
Ashcroft,
The sulfonylurea receptor.
1992,
Pubmed
Ashcroft,
Electrophysiology of the pancreatic beta-cell.
1989,
Pubmed
Ashcroft,
ATP-sensitive K+ channels and insulin secretion: their role in health and disease.
1999,
Pubmed
Assan,
Mefloquine-associated hypoglycaemia in a cachectic AIDS patient.
1995,
Pubmed
Bateman,
Quinine toxicity.
1986,
Pubmed
Batty,
A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria.
1998,
Pubmed
Bem,
Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions.
1992,
Pubmed
Bhatia,
Chloroquine-induced psychiatric complications.
1991,
Pubmed
Blackshear,
The effects of inhibition of gluconeogenesis on ketogenesis in starved and diabetic rats.
1975,
Pubmed
Bokvist,
Block of ATP-regulated and Ca2(+)-activated K+ channels in mouse pancreatic beta-cells by external tetraethylammonium and quinine.
1990,
Pubmed
Bokvist,
Effects of external tetraethylammonium ions and quinine on delayed rectifying K+ channels in mouse pancreatic beta-cells.
1990,
Pubmed
Brewer,
Fatal neurotoxicity of arteether and artemether.
1994,
Pubmed
Clement,
Association and stoichiometry of K(ATP) channel subunits.
1997,
Pubmed
Davis,
A safe and effective consecutive-infusion regimen for rapid quinine loading in severe falciparum malaria.
1990,
Pubmed
Davis,
Antimalarial drugs and glucose metabolism.
1997,
Pubmed
Davis,
Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial.
1996,
Pubmed
Edwards,
The pharmacology of ATP-sensitive potassium channels.
1993,
Pubmed
Evans,
Neurological, cardiovascular and metabolic effects of mefloquine in healthy volunteers: a double-blind, placebo-controlled trial.
1997,
Pubmed
Foley,
Quinoline antimalarials: mechanisms of action and resistance.
1997,
Pubmed
Gribble,
Properties of cloned ATP-sensitive K+ currents expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase
Hien,
Qinghaosu.
1993,
Pubmed
Inagaki,
Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor.
1995,
Pubmed
Inagaki,
A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels.
1996,
Pubmed
Isomoto,
A novel sulfonylurea receptor forms with BIR (Kir6.2) a smooth muscle type ATP-sensitive K+ channel.
1996,
Pubmed
Jaspers,
Tolerance of mefloquine chemoprophylaxis in Dutch military personnel.
1996,
Pubmed
Karschin,
KATP channel formation by the sulphonylurea receptors SUR1 with Kir6.2 subunits in rat dorsal vagal neurons in situ.
1998,
Pubmed
Liss,
Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons.
1999,
Pubmed
Nichols,
Adenosine triphosphate-sensitive potassium channels in the cardiovascular system.
1991,
Pubmed
Nosten,
Cardiac effects of antimalarial treatment with halofantrine.
1993,
Pubmed
Palmer,
Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy.
1993,
Pubmed
Proks,
Phentolamine block of KATP channels is mediated by Kir6.2.
1997,
Pubmed
,
Xenbase
Sakura,
Cloning and functional expression of the cDNA encoding a novel ATP-sensitive potassium channel subunit expressed in pancreatic beta-cells, brain, heart and skeletal muscle.
1995,
Pubmed
Sheiner,
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.
1979,
Pubmed
Tucker,
Truncation of Kir6.2 produces ATP-sensitive K+ channels in the absence of the sulphonylurea receptor.
1997,
Pubmed
,
Xenbase
